Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Pyrimethamine on BMS-986165 Pharmacokinetics in Healthy Males
NCT04086719Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration at Day 5 and Area under the concentration-time curve from time zero extrapolated to infinity at Day 5. Started Sep 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04086719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086719.